www.fdanews.com/articles/197153-european-commission-approves-takedas-adcetris-for-large-cell-lymphoma
European Commission Approves Takeda’s Adcetris for Large-Cell Lymphoma
May 15, 2020
The European Commission has approved Takeda’s Adcetris (brentuximab vedotin) as an adjunct treatment for adult patients with previously untreated systemic anaplastic large-cell lymphoma (sALCL).
The approval was based on the results of a phase 3 trial in which Adcetris plus cyclophosphamide, doxorubicin and prednisone demonstrated significant improvement in progression-free survival.
Adcetris is approved in the U.S. for several indications, including sALCL.